Clinical Trial Update: Combining Saxagliptin and Acarbose to Improve Postprandial Glycaemia in Type 2 Diabetes [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the combination of saxagliptin and acarbose to improve postprandial glucose in type 2 diabetes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Onglyza (Saxagliptin)
• Precose (acarbose)

Snippet

Sponsor: Zilin Sun | Conditions: Type 2 Diabetes | Phase 3 | Status: COMPLETED